Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
← catalyst calendarNCT06830044 · readout ≤ 590 d
Sponsored by Vanda Pharmaceuticals (industry) · VNDA — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
500estimated
Sites
38
Countries
Bulgaria, Czechia, Poland +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-03 | actual | When the study began enrolling |
| Primary completion | Mar 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Major Depressive Disorder (MDD)
Interventions
- Drug: Milsaperidone — also filed as VHX-896
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)
measured 6 weeks
Permalink · VNDA's whole pipeline · Catalyst calendar · Every registered study · What changed